TY - JOUR
T1 - Statistical methods for composite endpoints
AU - Hara, Hironori
AU - van Klaveren, David
AU - Kogame, Norihiro
AU - Chichareon, Ply
AU - Modolo, Rodrigo
AU - Tomaniak, Mariusz
AU - Ono, Masafumi
AU - Kawashima, Hideyuki
AU - Takahashi, Kuniaki
AU - Capodanno, Davide
AU - Onuma, Yoshinobu
AU - Serruys, Patrick W
N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2021/4/2
Y1 - 2021/4/2
N2 - Composite endpoints are commonly used in clinical trials, and time-to-first-event analysis has been the usual standard. Time-to-first-event analysis treats all components of the composite endpoint as having equal severity and is heavily influenced by short-term components. Over the last decade, novel statistical approaches have been introduced to overcome these limitations. We reviewed win ratio analysis, competing risk regression, negative binomial regression, Andersen-Gill regression, and weighted composite endpoint (WCE) analysis. Each method has both advantages and limitations. The advantage of win ratio and WCE analyses is that they take event severity into account by assigning weights to each component of the composite endpoint. These weights should be pre-specified because they strongly influence treatment effect estimates. Negative binomial regression and Andersen-Gill analyses consider all events for each patient -rather than only the first event - and tend to have more statistical power than time-to-first-event analysis. Pre-specified novel statistical methods may enhance our understanding of novel therapy when components vary substantially in severity and timing. These methods consider the specific types of patients, drugs, devices, events, and follow-up duration.
AB - Composite endpoints are commonly used in clinical trials, and time-to-first-event analysis has been the usual standard. Time-to-first-event analysis treats all components of the composite endpoint as having equal severity and is heavily influenced by short-term components. Over the last decade, novel statistical approaches have been introduced to overcome these limitations. We reviewed win ratio analysis, competing risk regression, negative binomial regression, Andersen-Gill regression, and weighted composite endpoint (WCE) analysis. Each method has both advantages and limitations. The advantage of win ratio and WCE analyses is that they take event severity into account by assigning weights to each component of the composite endpoint. These weights should be pre-specified because they strongly influence treatment effect estimates. Negative binomial regression and Andersen-Gill analyses consider all events for each patient -rather than only the first event - and tend to have more statistical power than time-to-first-event analysis. Pre-specified novel statistical methods may enhance our understanding of novel therapy when components vary substantially in severity and timing. These methods consider the specific types of patients, drugs, devices, events, and follow-up duration.
UR - http://www.scopus.com/inward/record.url?scp=85103803018&partnerID=8YFLogxK
U2 - https://doi.org/10.4244/EIJ-D-19-00953
DO - https://doi.org/10.4244/EIJ-D-19-00953
M3 - Article
C2 - 32338610
SN - 1774-024X
VL - 16
SP - e1484-e1495
JO - EuroIntervention
JF - EuroIntervention
IS - 18
ER -